|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2005-1-31
|
|
pubmed:abstractText |
Patients with severe persistent asthma who are inadequately controlled despite treatment according to current asthma management guidelines have a significant unmet medical need. Such patients are at high risk of serious exacerbations and asthma-related mortality.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0105-4538
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
60
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
302-8
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:15679714-Anti-Asthmatic Agents,
pubmed-meshheading:15679714-Antibodies, Anti-Idiotypic,
pubmed-meshheading:15679714-Antibodies, Monoclonal,
pubmed-meshheading:15679714-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:15679714-Asthma,
pubmed-meshheading:15679714-Emergency Medical Services,
pubmed-meshheading:15679714-Humans,
pubmed-meshheading:15679714-Immunoglobulin E,
pubmed-meshheading:15679714-Randomized Controlled Trials as Topic,
pubmed-meshheading:15679714-Severity of Illness Index
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma.
|
|
pubmed:affiliation |
Hôpital Arnaud de Villeneuve, Montpellier, France.
|
|
pubmed:publicationType |
Journal Article,
Meta-Analysis
|
